N/A N=28 Transcranial Laser Therapy for Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Hamilton Depression Rating Scale (HAM-D 17) Score — -11.7; -5.3; -15.7; -6.1 units on a scale — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=596 Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Phase 2 N=132 Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12 — -5.4; -6.2 units on a scale
Phase 3 N=109 Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Osteoporosis · Prostate Cancer
Primary: Freedom From Any Bone Fracture (FABF) Rate at Three Years — 98.0; 97.4 percentage of participants — p=0.95
Phase 2 N=214 The Study of AZD8529 for Smoking Cessation in Female Smokers
Tobacco Use Disorder
Primary: Abstinence — 10; 11 Participants
Phase 3 N=951 The Plecanatide Chronic Idiopathic Constipation (CIC) Study
Chronic Idiopathic Constipation
Primary: Overall Responder 9/12 Weeks — 18.6; 16.8; 19.0; 10.7 % of Overall Responder 9/12 weeks
Phase 2 N=35 A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA
Iron Deficiency Anemia (IDA)
Primary: Maximum Serum Concentration (Cmax) — 157; 310 µg/mL
Phase 2 N=36 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children
Asthma
Primary: Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A — 12.8188; 16.3412; 10.1960 Microgram (ug) per mL
N/A N=181 A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement
Wounds and Injuries
Primary: Number of Inpatient Operating Room Debridements — 9; 13; 52; 41 Participants — p=0.6770
N/A N=39 Melody PB1016 Surveillance Study
Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects
Primary: Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months — 25 Participants
N/A N=12 Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)
Post Thrombotic Syndrome · Deep Vein Thrombosis · Venous Stasis Syndrome
Primary: Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms — 32 mirco coulombs (0 to 50)
N/A N=39 [11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Type2 Diabetes
Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875
Phase 4 N=1,270 Smoking Cessation in Hospitalized Smokers
Smoking Cessation
Primary: Percentage of Participants With 30-day Abstinence — 18.0; 23.4; 22.1; 18.7 percentage of participants
Phase 2 N=6 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis
Calcinosis
Primary: Change in Dermatomyositis-associated Calcinosis of a Single Lesion by Assessing Its Severity as Measured by a Difference in Physician Calcinosis Visual Analog Scales…
Phase 3 N=449 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Smallpox
Primary: To Determine the Number of Participants With Adverse Events — 134; 30 Participants